Canine Warts Treatment: Papilloma Options for Dogs

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Most warts on dogs are papillomas, and most papillomas go away on their own. In a study of 40 dogs with naturally occurring oral papillomatosis, none received antiviral therapy and time to clinical regression ranged from 1 month to 1 year [1]. In a separate series of 44 dogs with biopsy-confirmed papillomas on the paws, 34 lesions resolved, and 25 of those resolved within three weeks of the biopsy itself [2]. That is the single most important fact in canine papilloma treatment: the first decision is usually whether to treat at all, not which drug to use.

When treatment is needed, the options are narrow and well defined. They include watchful waiting, surgical removal or cryotherapy for a single troublesome lesion, azithromycin, interferon, autogenous or experimental vaccines, and in refractory cases radiation therapy. Each has a specific place. This guide explains how to tell a routine papilloma from one that needs a biopsy, what each treatment actually does, and how to judge whether your dog is on the normal recovery timeline or falling behind it.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance: The Canine Papilloma Decision Path

What a Canine Papilloma Actually Is

A papilloma is a benign epithelial growth caused by a papillomavirus. In dogs, canine papillomavirus type 1 (CPV1) is considered responsible for most oral cases and several forms of cutaneous papillomatosis [1]. The virus infects basal keratinocytes, the dividing cells at the base of the skin and mucosa, and drives them to proliferate into the cauliflower-like bumps owners recognize as warts.

Papillomavirus infection in dogs is not one disease. It is a family of conditions with different behaviors, different typical patients, and different treatment thresholds. Getting the category right matters more than picking a drug.

Oral papillomatosis in young dogs

Classical oral papillomatosis is a disease of young dogs. Lesions appear as whitish, verrucous, hyperkeratotic papules, typically 1 to 2.7 mm in size, clustered on the lips, gums, tongue, and oral mucosa [3]. The immune response is what ends the infection. Antibody titers against the CPV1 L1 capsid protein peak around the time of clinical regression, and regressor dogs develop circulating IgG that protects them against reinfection [1][8]. This is why the warts shrink and disappear rather than needing to be cut out one by one.

The timeline is variable but usually measured in weeks to a few months. In one naturally occurring cohort, regression took between 1 month and 1 year [1]. In practice, the majority of young dogs clear their oral warts well within that window, and the long tail of that range reflects the minority of dogs with slower immune clearance.

Cutaneous inverted papillomas

Cutaneous papillomas are the skin equivalent, and they come in two microscopic patterns. In a retrospective series of 44 dogs with pedal papillomatosis, histopathology documented 33 noninverted papillomas and 11 inverted papillomas [2]. Inverted papillomas grow downward into the underlying tissue rather than outward, which makes them look like a firm nodule rather than a classic wart. The median age at presentation in that series was 4 years, dogs most often presented with lameness or paw licking and chewing, only one paw was affected in 35 of 44 cases, and front paws were affected more often than back paws [2].

That series is useful for owners because it shows how often these lesions resolve on their own. Twenty-one dogs received no additional treatment after biopsy, and 15 of those resolved without further intervention [2]. The biopsy itself may have triggered resolution in many of them, since 25 of the 34 resolved lesions did so within three weeks of sample collection [2].

The rare malignant transformation

Papillomas are benign, but papillomaviruses are oncogenic, and malignant transformation is a documented, if uncommon, outcome. In one case report, a 3-year-old Labrador retriever cross had multiple multifocal verrucous lesions confined to the oral cavity. The papillomas persisted despite multiple surgical ablations, azithromycin, interferon α-2b, alternative medicines, and off-label immunostimulant use. After 1 year and 6 months, an aggressive lesion developed at the left mandibular first molar and progressed to a well-differentiated invasive oral squamous cell carcinoma. CPV-1 DNA was present in the carcinoma, and coinfection with another papillomavirus was excluded by multiple polymerase chain reaction tests using various primers [5]. The dog was ultimately euthanized because of poor quality of life [5].

A second case followed a similar arc. A 3-year-old border collie with CPV-1-positive oral papillomas resistant to standard-of-care treatment developed lesions consistent with squamous cell carcinoma [7]. These cases are the reason persistent papillomatosis is not treated as a cosmetic problem.

The First Decision: Treat or Wait

Watchful waiting is a legitimate medical plan, not a failure to act. The reasoning is straightforward. The immune system clears most papillomavirus infections, antibody titers rise as regression approaches, and the resulting immunity is protective [1][8]. Intervening in a wart that is about to disappear on its own exposes the dog to anesthesia, medication side effects, or both for no benefit.

Waiting is appropriate when the dog fits the classic picture:

• The dog is young, typically under 2 years old.
• Lesions are oral and multiple, matching the expected distribution.
• The dog is eating, drinking, and behaving normally.
• No lesion is bleeding, ulcerating, or growing rapidly.
• The dog is not receiving immunosuppressive medication.

Waiting is not appropriate when any of the following apply:

• The dog is an adult with a new wart, especially a first-time lesion.
• The dog is receiving prednisone, cyclosporine, or other immunosuppressive therapy.
• A lesion has changed character, become painful, or started to bleed.
• Warts are obstructing eating, breathing, or vision.
• Lesions have persisted beyond roughly 3 months without any sign of shrinking.

The reason immunosuppression raises the threshold so sharply is documented. A 4-year-old spayed female toy fox terrier developed multiple epidermal hamartomas and squamous cell carcinomas in situ during 3 years of chronic prednisone and cyclosporine treatment for immune-mediated nonregenerative anemia. Immunohistochemical staining was positive for papillomavirus antigen in both the benign lesions (19 of them) and the malignant lesions (8 of them) [4]. Treatment with interferon-alpha was discontinued after 2 weeks because of diarrhea and a further increase in liver enzymes, and new lesions continued to develop during the year after both drugs were stopped [4]. In dogs whose immune system is being deliberately suppressed, papillomavirus lesions deserve a lower threshold for biopsy and a higher level of suspicion.

How the Decision Flows

The path from "my dog has a wart" to a treatment plan follows a predictable sequence. The key branch points are the dog's age and immune status, and whether the lesion is behaving like a routine papilloma.

flowchart TD
    [Wart found] --> [Assess age and immune status]
    [Assess age and immune status] --> {Young and healthy}
    {Young and healthy} --> [Watchful waiting]
    {Young and healthy} --> [Weekly photos and recheck]
    [Assess age and immune status] --> {Adult or immunosuppressed}
    {Adult or immunosuppressed} --> [Biopsy first]
    [Biopsy first] --> [Confirm papilloma]
    [Biopsy first] --> [Rule out carcinoma]
    [Watchful waiting] --> [Resolved within three months]
    [Watchful waiting] --> [Persistent or worsening]
    [Persistent or worsening] --> [Consider azithromycin]
    [Persistent or worsening] --> [Consider surgery or cryotherapy]
    [Consider azithromycin] --> [Reassess in two weeks]
    [Consider surgery or cryotherapy] --> [Reassess at recheck]
    [Reassess in two weeks] --> [Referral for severe or refractory cases]
    [Reassess at recheck] --> [Referral for severe or refractory cases]

Watchful Waiting: How to Do It Properly

Watchful waiting fails when it is passive. It works when the owner and veterinarian are actively tracking the lesions against a timeline.

Take dated photographs. Photograph the warts weekly from the same angle and distance. A wart that looks unchanged in memory may be visibly smaller in a side-by-side comparison. This is the single most useful thing an owner can do during the waiting period.

Count and map the lesions. Note how many there are and where. New lesions appearing while old ones shrink is common early in the course and does not necessarily mean treatment has failed.

Monitor function, not just appearance. The questions that matter are whether the dog can eat comfortably, whether it is pawing at its mouth, whether it is lame, and whether it is licking or chewing at a paw. A wart that is cosmetically impressive but functionally silent is a wart that can keep waiting.

Set a review date. A reasonable checkpoint is 4 to 6 weeks. If there is no reduction in size or number by that point, the conversation shifts toward treatment.

Know the outer limit. Regression in the published cohort ranged from 1 month to 1 year [1]. A wart still present and unchanged at 3 months is a wart that deserves active management rather than continued waiting.

Azithromycin for Canine Papillomatosis

Azithromycin is the most studied medical treatment for canine papillomatosis and the one most commonly initiated after a biopsy confirms the diagnosis [2]. It is an azalide macrolide antibiotic that has an established role in treating papillomatosis in humans, which is the rationale for its use in dogs [3].

What the evidence shows

The strongest evidence is a prospective, randomized, double-blinded, placebo-controlled trial of 17 dogs with oral papillomatosis (12 dogs) or cutaneous papillomatosis (5 dogs). Azithromycin was given at 10 mg/kg orally every 24 hours for 10 days. Treatment significantly decreased clinical scores compared with placebo, and skin lesions disappeared in 10 to 15 days in the treated group. There was no recurrence over an 8-month follow-up, and no adverse effects were seen in either group [3].

In the placebo group, one dog had spontaneous regression by day 41, but lesions were still evident at day 50 in the remaining six dogs [3]. That split is a useful reminder of why a control group matters. Without it, the single spontaneous regression would look like a treatment success.

In the 44-dog pedal papilloma series, azithromycin was the most commonly reported treatment initiated after biopsy collection [2].

Dosing and practical use

The label-sourced dose in the published trial is 10 mg/kg orally once daily for 10 days [3]. This is the regimen with the strongest supporting data. Do not extend the course or repeat it without veterinary direction. Azithromycin is a prescription antibiotic, and in the United States it is not available over the counter for this purpose.

Owners should understand two things about this drug. First, it is being used for its immunomodulatory effect on papillomavirus lesions, not to treat a bacterial infection. Second, the trial that supports it was small, with 10 treated dogs, so the evidence is real but modest in scale [3].

When azithromycin is the right choice

Azithromycin fits best for a dog with confirmed papillomatosis that has failed an appropriate period of watchful waiting, or for a dog with lesions that are spreading or interfering with daily life but are not surgical candidates. It is a reasonable first medical option before moving to more invasive or experimental treatments.

Surgical Excision and Cryotherapy

Surgery is the right answer for a specific problem, not for a diffuse disease. Removing one large or mechanically troublesome wart is straightforward. Removing twenty oral warts is not, and the published record shows why.

In the 44-dog pedal papilloma series, 34 papillomas resolved in total, and 25 of those resolved within three weeks after biopsy collection. Twenty-one dogs received no additional treatment, and 15 of those resolved [2]. The implication is that many single pedal papillomas resolve after the diagnostic procedure itself. That makes excision a reasonable combined diagnostic and therapeutic step for a solitary lesion causing lameness.

Surgery is also the appropriate first move when malignancy is a concern, because the excised tissue goes to the pathologist. A wart that is removed and confirmed benign has answered the most important question.

Cryotherapy, or freezing the lesion, is a destructive option for small, accessible, solitary warts. It preserves the same logic as excision: it is a local treatment for a local problem.

Surgery has clear limits in severe disease. In the case of the Labrador cross with persistent oral papillomatosis, multiple surgical ablations did not resolve the condition [5]. In the Siberian husky with severe oral papillomatosis, the disease was refractory to surgical treatment over a 6-month period [6]. Repeatedly cutting warts out of a dog with widespread papillomatosis treats the symptom and not the cause.

Interferon

Interferon α-2b has been used in canine papillomavirus disease, but the published experience is mixed and includes a notable failure.

In the case of the Labrador cross with persistent CPV-1 oral papillomas, interferon α-2b was among the treatments that failed to control the disease before malignant transformation [5]. In the toy fox terrier with papillomavirus-associated squamous cell carcinoma in situ, interferon-alpha treatment was discontinued after 2 weeks because of diarrhea and a further increase in liver enzymes [4].

That does not make interferon useless. It means the evidence base is thin, the response is not guaranteed, and side effects can be significant enough to stop treatment. Interferon is best positioned as a referral-level option for severe or refractory cases rather than a routine first-line choice. Owners considering it should ask their veterinarian what specific outcome is being targeted and how long a trial is reasonable before declaring it a failure.

Vaccines for Severe or Persistent Papillomatosis

Vaccination is the most scientifically interesting area in canine papillomavirus treatment, and it splits into two distinct concepts: preventive vaccination and therapeutic vaccination.

Preventive vaccination

The canine oral papillomavirus model is one of the best-studied systems in papillomavirus immunology. Recombinant adenoviral vaccines expressing codon-optimized COPV E1, E2, E4, and E7 genes were tested in beagle dogs. Complete protection from COPV-induced papillomas was achieved with vaccine combinations expressing E1 plus E2, or E1 plus E2 plus E4 plus E7. Two of six dogs immunized with E4 plus E7 developed oral papillomas, and all six control dogs immunized with an adenovirus expressing human papillomavirus type 16 L1 developed papillomas [9]. In two follow-up studies, subcutaneous immunization with one or two doses of adenovirus expressing COPV E1 and E2 protected more than 90 percent of challenged dogs from wart formation, while all eight control dogs developed papillomas at multiple sites. Protection was accompanied by significant interferon-gamma responses to COPV E1 and E2 peptides [9].

Other vaccine platforms have produced similar protection. A glutathione S-transferase COPV L1 fusion protein expressed in bacteria formed pentamers rather than virus-like particles but completely protected dogs from high-dose viral infection of the oral mucosa [10]. Particle-mediated DNA delivery of a plasmid encoding the COPV L1 gene to cutaneous and oral mucosal sites protected all vaccinated dogs against COPV challenge, while five of six control dogs developed papillomas [11]. Particle-mediated delivery of COPV L1 also resulted in no detectable COPV DNA after challenge, suggesting the vaccine may induce virus clearance [12].

These are experimental vaccines used in research settings. They are not commercial products available for general veterinary use.

Therapeutic and autogenous vaccination

Therapeutic vaccination uses the vaccine to treat existing disease rather than prevent it. A 16-month-old female Siberian husky with severe oral papillomatosis that had not regressed spontaneously and was refractory to surgery over 6 months achieved regression of the papillomas after a series of experimental vaccinations with canine oral papillomavirus major coat protein L1, which self-assembles into virus-like particles. The vaccine acted therapeutically, causing regrown papillomas to shrink, and no side effects were noted [6].

Autogenous vaccination, made from the dog's own lesion tissue, has also been attempted in severe cases. In one naturally occurring nonregressing COPV infection, the papillomas proved refractory to surgical and medical treatments, including autogenous vaccination and vaccination with capsid L1 virus-like particles. High levels of induced anti-L1 antibodies appeared to have no effect on the infection, and the papillomas spread to esophageal mucosa, perioral haired skin, and remote cutaneous sites [13]. Critically, the virus isolated from that dog was sequenced and showed no differences from the COPV prototype, and experimental infection of beagle dogs with the isolate produced uncomplicated oral warts that regressed normally [13]. The problem was the host immune response, not the virus.

That finding shapes how owners should think about vaccine therapy. In dogs with severe, nonregressing papillomatosis, the underlying issue is often a specific defect in host immunity rather than an unusually aggressive virus [13]. Vaccine therapy can work, as the husky case shows, but it is not a reliable fix, and failure does not mean the vaccine was made incorrectly.

There is also a documented risk specific to live papillomavirus vaccines. A spectrum of proliferative cutaneous lesions occurred in 12 dogs at the injection site of a live canine oral papillomavirus vaccine, including epidermal hyperplasia, epidermal cysts, squamous papilloma, basal cell epithelioma, and squamous cell carcinoma. Papillomavirus antigen was detected in five of the 12 masses, and transmission studies showed the material could protect puppies against challenge even though it did not produce oral papillomas on scarified mucosa [14]. This is a historical finding from a vaccine type no longer in routine use, but it is a reminder that papillomavirus vaccines are not biologically inert.

Other Reported Options

Two additional approaches appear in the literature with limited evidence.

Topical molecular iodine. A case report described a 2-year-old dog with a canine oral papilloma treated with 300 ppm molecular iodine applied to a saturated paper towel for 1.5 minutes twice daily. The lesion steadily diminished and was no longer detectable by clinical examination at 4 weeks, with no recurrence after 1.5 years [15]. This is a single case, so it should be treated as a promising anecdote rather than an established protocol.

Dihydroartemisinin. Dihydroartemisinin, an antimalarial drug with selective cytotoxicity against papillomavirus-expressing cells, was applied to the oral mucosa of dogs challenged with canine oral papillomavirus. Despite intermittent application, it strongly inhibited viral-induced tumor formation [16]. This is preclinical work, not a clinical treatment protocol.

Definitive radiation therapy. For refractory oral papillomatosis with malignant transformation, definitive external beam radiation has produced durable remission. A 3-year-old border collie with incompletely excised malignant tumors received 45 Gy in 15 daily fractions of 3 Gy, while the remaining oral cavity received 27 Gy in 15 daily fractions of 1.8 Gy to treat disseminated oral papillomatosis. A 2-week treatment delay was required because of grade 3 mucositis. The dog remained in complete remission 10 months after radiotherapy, with no tumor recurrences reported by the owners more than 1 year after treatment [7]. This is a referral-level option for a serious situation.

Treatment Comparison Table

Common Mistakes Owners Make

Waiting too long on an adult-onset wart. Oral papillomatosis is a young dog disease. A new wart in a middle-aged or older dog is a different clinical problem and should be sampled.

Treating the whole dog for one wart. Systemic medication for a single lesion that could be excised or simply monitored exposes the dog to drug effects for a problem that is local.

Stopping azithromycin early. The published regimen is 10 days [3]. A partial course does not have supporting data.

Assuming a shrinking wart means the problem is over. Regression is expected and good. It does not remove the need for a final recheck to confirm complete resolution.

Ignoring immunosuppressive therapy as a risk factor. Dogs on prednisone or cyclosporine have a documented association between papillomavirus and squamous cell carcinoma in situ [4]. Any new growth in these dogs deserves prompt evaluation.

Using human products on dog warts. Nothing in the veterinary literature supports this, and some topical human wart treatments are irritants that can cause significant tissue damage.

Welfare and Safety Points

Papillomavirus is contagious between dogs. The virus spreads through direct contact, and dogs with active oral papillomatosis can infect other dogs in the household or at daycare, training class, and the dog park. The canine oral papillomavirus model depends on this transmissibility, which is how challenge studies are conducted [9][11].

Practical measures during an active infection include keeping the dog's food and water bowls separate, avoiding shared toys, and limiting close nose-to-nose contact with other dogs until lesions have resolved. Dogs with oral lesions should not share chews or tug toys.

For the affected dog, the welfare priorities are comfort and function. A dog that is eating normally and behaving normally is not suffering from its warts. A dog that is dropping food, pawing at its mouth, drooling excessively, or refusing to eat is telling you the lesions are interfering, and that changes the treatment threshold.

Anesthesia carries its own risks, and this matters when weighing surgery for a benign, self-limiting lesion. The calculus is different for a single problematic wart than for a diffuse crop of warts that will likely disappear on their own.

When a Biopsy Is Not Optional

Biopsy is the dividing line between benign papillomatosis and something more serious. There are specific situations where it should not be skipped or delayed.

Adult-onset lesions. A first wart in a mature dog is not the typical presentation of viral papillomatosis.

Immunosuppressed dogs. Dogs receiving prednisone, cyclosporine, or other immunosuppressive drugs have a documented risk of papillomavirus-associated squamous cell carcinoma in situ [4]. Dogs with X-linked severe combined immunodeficiency remain at increased risk for cutaneous papillomavirus infections and their associated neoplasms even after bone marrow transplant [17].

Lesions that fail to respond. In the Labrador cross, the papillomas persisted through surgery, azithromycin, interferon, and other treatments before transforming into an invasive squamous cell carcinoma after 18 months [5]. Persistence despite appropriate treatment is itself a reason to re-sample.

Lesions that change. Rapid growth, ulceration, bleeding, or a change in texture all warrant sampling.

Lesions at unusual sites. Papillomavirus-associated lesions have been documented at sites beyond the oral cavity, including perioral haired skin, remote cutaneous sites, and esophageal mucosa in a nonregressing infection [13]. Cutaneous lesions at injection sites have also been documented with a live papillomavirus vaccine [14].

Limitations and When to Contact a Veterinarian

This article describes general patterns in canine papillomatosis. Individual dogs vary in immune response, lesion behavior, and tolerance for treatment, and no article can substitute for an examination of your dog's specific lesions.

Contact a veterinarian promptly if any of the following occur:

• A new wart appears in a dog older than 2 years.
• Your dog is receiving immunosuppressive medication and develops any new growth.
• A wart grows rapidly, ulcerates, bleeds, or changes color or texture.
• Your dog is dropping food, drooling excessively, refusing to eat, or losing weight.
• Your dog is lame, limping, or constantly licking or chewing at a paw.
• Warts have been present for more than 3 months without shrinking.
• Warts are spreading to new sites while existing lesions remain unchanged.
• Your dog has been treated with azithromycin for 10 days with no improvement.
• Your dog develops diarrhea, vomiting, or lethargy during any treatment for papillomatosis.
• You are considering any treatment not prescribed by your veterinarian.

Frequently Asked Questions

Do dog warts go away on their own?

Yes, most do. In a study of 40 dogs with naturally occurring oral papillomatosis who received no antiviral therapy, regression occurred between 1 month and 1 year [1]. In a series of 44 dogs with pedal papillomas, 34 lesions resolved, and 25 resolved within three weeks of the biopsy [2].

How long should I wait before treating my dog's warts?

A reasonable checkpoint is 4 to 6 weeks with weekly photographs. If there is no reduction in size or number by 3 months, active treatment is warranted. The published range for spontaneous regression extends up to 1 year, but a wart that has not changed at all by 3 months is unlikely to resolve without help [1].

Is azithromycin safe for dogs with papillomas?

In a controlled trial, azithromycin at 10 mg/kg orally once daily for 10 days produced no adverse effects in either the treatment or placebo group, and lesions disappeared in 10 to 15 days [3]. It is a prescription medication and the dose should come from your veterinarian.

Can I use human wart remover on my dog?

No. There is no veterinary evidence supporting human topical wart products on dogs, and some contain irritants that can damage tissue. The treatments with published support in dogs are azithromycin, surgery, and vaccine-based approaches in referral settings.

Are dog warts contagious to other dogs?

Yes. Papillomavirus spreads between dogs through direct contact, which is the basis of the experimental challenge models used to study the disease [9][11]. Keep food bowls, toys, and chews separate while lesions are active.

Can a dog wart turn into cancer?

It can, though this is uncommon. A CPV-1 oral papilloma in a 3-year-old dog transformed into an invasive oral squamous cell carcinoma after 18 months of persistent disease despite multiple treatments [5]. A second case of refractory oral papillomatosis also developed lesions consistent with squamous cell carcinoma [7].

Why did my dog get warts as an adult?

Adult-onset papillomatosis is atypical and warrants a biopsy. Immunosuppression is a known risk factor. A dog on chronic prednisone and cyclosporine developed multiple papillomavirus-associated squamous cell carcinomas in situ [4]. Adult-onset lesions should be sampled rather than assumed benign.

Do dogs need treatment if the warts are not bothering them?

Often no. If the dog is a young animal with typical oral lesions, is eating and behaving normally, and is not immunosuppressed, watchful waiting with regular monitoring is the appropriate first step. Treatment is reserved for lesions that interfere with function, persist beyond the expected window, or raise concern for malignancy.

Related Articles

• Canine Hyperadrenocorticism: Treatment Options and Monitoring
• Canine Parasitic Skin Infections: Diagnosis and Treatment Options
• Warts On Dogs: Comprehensive Veterinary Reference Guide
• Papillomas In Dogs: Comprehensive Veterinary Reference Guide
• Cat Viral Conjunctivitis Treatment
• Ferret Lymphoma: Diagnosis, Staging, and Treatment Options
• Equine Sarcoid: Types, Causes, and Treatment Options

Sources

1. Antibody titres against canine papillomavirus 1 peak around clinical regression in naturally occurring oral papillomatosis.
2. Canine pedal papilloma identification and management: a retrospective series of 44 cases.
3. Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double-blinded, placebo-controlled clinical trial.
4. Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine.
5. Malignant Transformation of a Canine Papillomavirus Type 1-Induced Persistent Oral Papilloma in a 3-Year-Old Dog.
6. Resolution of persistent oral papillomatosis in a dog after treatment with a recombinant canine oral papillomavirus vaccine.
7. Successful definitive radiation treatment of refractory canine oral papillomatosis.
8. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.
9. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.
10. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
11. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.
12. Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination.
13. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection.
14. Cutaneous neoplasms in dogs associated with canine oral papillomavirus vaccine.
15. Treatment of a Canine Oral Papilloma With Topical Molecular Iodine: A Case Report With Implications for Antiviral Therapy in Humans.
16. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo.
17. Keratinocyte antiviral response to Poly(dA:dT) stimulation and papillomavirus infection in a canine model of X-linked severe combined immunodeficiency.